The differences between neutron and proton density distributions at large nuclear radii in stable nuclei were determined. Two experimental methods were applied: nuclear spectroscopy analysis of the antiproton annihilation residues one mass unit lighter than the target mass and the measurements of strong-interaction effects on antiprotonic x rays. Assuming the validity of two-parameter Fermi neutron and proton distributions at these large radii, the conclusions are that the two experiments are consistent with each other and that for neutron rich nuclei it is mostly the neutron diffuseness which increases and not the half-density radius. The obtained neutron and proton rms radii differences are in agreement with previous results.

The nuclear periphery was studied by using antiprotons. Two experimental methods were applied: analysis of the antiproton annihilation residues one mass unit lighter than the target mass by nuclear spectroscopy and the measurement of strong interaction effects on antiprotonic level widths and shifts. 26 isotopes from a wide range of mass numbers (40<A<238) were investigated. The gathered antiprotonic-atom data were compared with the results obtained using hadron scattering methods and with some expectations from theoretical approaches.

Heavy-ion collisions often produce fusion barrier distributions with structures displaying a fingerprint of couplings to highly collective excitations. Similar distributions can be obtained from large-angle quasielastic scattering, although in this case, the role of the many weak direct-reaction channels is unclear. For 20Ne+90Zr, we have observed the barrier structures expected for the highly deformed neon projectile; however, for 20Ne+92Zr, we find significant extra absorption into a large number of noncollective inelastic channels. This leads to smearing of the barrier distribution and a consequent reduction in the “resolving power” of the quasielastic method

The x-ray cascade from antiprotonic atoms was studied for 208 Pb and 209 Bi. Widths and shifts of the levels due to the strong interaction were determined. Using modern antiproton-nucleus optical potentials, the neutron densities in the nuclear periphery were deduced. Assuming two-parameter Fermi distributions (2pF) describing the proton and neutron densities, the neutron rms radii were deduced for both nuclei. The difference of neutron and proton rms radii r np equal to 0.16 ± (0.02) stat ± (0.04) syst fm for 208 Pb and 0.14 ± (0.04) stat ± (0.04) syst fm for 209 Bi were determined, and the assigned systematic errors are discussed. The r np values and the deduced shapes of the neutron distributions are compared with mean field model calculations.

Highly localized radiotherapy with radionuclides is a commonly used treatment modality for patients with unresectable solid tumors. Herein, we propose a novel α-nanobrachytherapy approach for selective therapy of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. This uses local intratumoral injection of 5-nm-diameter gold nanoparticles (AuNPs) labeled with an α-emitter (211At), modified with polyethylene glycol (PEG) chains and attached to HER2-specific monoclonal antibody (trastuzumab). The size, shape, morphology, and zeta potential of the 5 nm synthesized AuNPs were characterized by TEM (Transmission Electron Microscopy) and DLS (Dynamic Light Scattering) techniques. The gold nanoparticle surface was modified by PEG and subsequently used for antibody immobilization. Utilizing the high affinity of gold for heavy halogens, the bioconjugate was labelled with 211At obtained by α irradiation of the bismuth target. The labeling yield of 211At was greater than 99%. 211At bioconjugates were stable in human serum. Additionally, in vitro biological studies indicated that 211At-AuNP-PEG-trastuzumab exhibited higher affinity and cytotoxicity towards the HER2-overexpressing human ovarian SKOV-3 cell line than unmodified nanoparticles. Confocal and dark field microscopy studies revealed that 211At-AuNP-PEG-trastuzumab was effectively internalized and deposited near the nucleus. These findings show promising potential for the 211At-AuNP-PEG-trastuzumab radiobioconjugate as a perspective therapeutic agent in the treatment of unresectable solid cancers expressing HER2 receptors.